Trial Profile
Sequential use of temsirolimus (TEM) in patients with metastatic renal cell carcinoma (mRCC): Safety and efficacy following failure of receptor tyrosine kinase inhibitor (TKI) treatment.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Mar 2010
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 05 Mar 2010 Results were presented at the ASCO 2010 Genitourinary Cancers Symposium.
- 05 Mar 2010 New trial record